COGNITE
5.10.2021 13:02:10 CEST | Business Wire | Press release
In the midst of the largest industrial revolution, Cognite , a leader in industrial digitalization, announced the release of The Definitive Guide To Industrial DataOps . A first for the industry, the book defines and explains the emerging discipline of Industrial DataOps in language crafted for both business and IT professionals, while addressing the urgency driven by accelerating, data-driven shifts that modern organizations now navigate. The insights and industry expertise captured in the book also offer organizations practical advice on successful Industrial DataOps adoption and scaling. A request for proposal (RFP) guide, and a self-assessment to evaluate organizational readiness and map out challenges, round out the actionable insights and tools covered in the book.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005582/en/
Industrial DataOps is already becoming a driving force in industrial transformations, helping accelerate digital maturity, enabling data teams to deliver more digital products, and realizing more operational value at scale. In a 2020 survey of global companies, McKinsey found organizations that embedded DataOps could see the volume of new features increase by 50 percent because data automation enables quicker development iterations.
“Data trust comes from connecting the dots between desired outcomes and relevant use-case-oriented data products,” says Forrester VP, Principal Analyst Michele Goetz. “An Industrial DataOps platform brings context to data conditions and ensures business impacting data anomalies are caught early to mitigate costly issues. A DataOps platform also ensures data complies with data models and output standards to drive results from event-based intelligence inside processes.”
‘The Definitive Guide to Industrial DataOps’ was written to de-hype industrial digitalization and to help make sense of how Industrial DataOps allows organizations to manage complex data. The book’s structure reflects the journey that industrial companies will take as they evaluate, adopt, and scale Industrial DataOps across their organizations. The early chapters cover the urgency of Industrial DataOps and get readers to take stock of their industrial organizations’ digital maturity. The core chapters address the discipline itself, its key principles, and how to best extract value from data, while the final chapters define the way forward: scaling Industrial DataOps and putting it into practice.
“Industrial DataOps is a crucial and necessary tool to make digital transformation possible in asset-intensive industries,” says John Markus Lervik, CEO and co-founder of Cognite. “It illustrates how to connect data from the IT and OT source to the data consumer with contextual tips that will empower organizations of all sizes to use it, innovate off of it, and reshape operations for efficiency, profitability, and sustainability. It is the strongest driver of change that will propel the industry forward, and this book will help companies as they navigate their way and capture immediate value at scale.”
“To make the promise of Industrial DataOps a reality for enterprises, ´The Definitive Guide to Industrial DataOps´ serves as a critical manual to not only understand this novel software category, but as well how it accelerates innovation and reduces time-to-value at each stage of a digital operations transformation,” says Pascal Brosset, Industry X Production & Operations Lead at Accenture.
The full book is available for download for free: The Definitive Guide To Industrial DataOps
About Cognite
Cognite is a global industrial SaaS company that was established with one clear vision: to rapidly empower industrial companies with contextualized, trustworthy, and accessible data to help drive the full-scale digital transformation of asset-intensive industries around the world. Our core Industrial DataOps platform, Cognite Data Fusion™, enables industrial data and domain users to collaborate quickly and safely to develop, operationalize, and scale industrial AI solutions and applications to deliver both profitability and sustainability. Visit us at www.cognite.com and follow us on Twitter @CogniteData or LinkedIn: https://www.linkedin.com/company/cognitedata .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005582/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom